Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

[Evaluation of dissolution of osmotic-controlled release paliperidone tablets using the reciprocating cylinder method].

Nagata S, Jin-nai A, Hirai K, Baba M, Higashi K, Tanaka Y.

Yakugaku Zasshi. 2013;133(3):405-10. Epub 2012 Dec 21. Japanese.

2.

[The delivery mechanism of micro-porous osmotic pump tablets].

Zhao XL, Li Q, Gong XF, Li SM.

Yao Xue Xue Bao. 2007 Feb;42(2):226-30. Chinese.

PMID:
17518057
3.
4.

A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.

Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Eerdekens M, Battisti WP, Palumbo JM.

Int Clin Psychopharmacol. 2007 Sep;22(5):299-308. Erratum in: Int Clin Psychopharmacol. 2007 Nov;22(6):387.

PMID:
17690599
5.

Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.

Fowler JA, Bettinger TL, Argo TR.

Clin Ther. 2008 Feb;30(2):231-48. doi: 10.1016/j.clinthera.2008.02.011. Review.

PMID:
18343262
6.

[Quality evaluation of magnesium oxide tablets using acid neutralization test and dissolution test].

Inoue C, Kogure T, Kamata A, Ishihara M, Muraoka R, Tatsumi A, Tanaka K, Takeshita H, Hamaguchi T, Tagawa N, Kobayashi Y, Kadobayashi M.

Yakugaku Zasshi. 2007 Dec;127(12):2085-9. Japanese.

7.

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A.

Biol Psychiatry. 2007 Dec 15;62(12):1363-70. Epub 2007 Jun 28.

PMID:
17601495
9.
11.

Dissolution testing of sublingual tablets: a novel in vitro method.

Rachid O, Rawas-Qalaji M, Simons FE, Simons KJ.

AAPS PharmSciTech. 2011 Jun;12(2):544-52. doi: 10.1208/s12249-011-9615-0. Epub 2011 Apr 27.

12.

[Controlled release of prednisolone from suppository prepared using powder of pulverized tablet].

Tatsumi A, Oda S, Nakamoto T, Muraoka R, Takahashi Y, Tanaka K, Shikata T, Tatsumi S, Tagawa N, Kobayashi Y, Hamaguchi T, Kadobayashi M.

Yakugaku Zasshi. 2008 Apr;128(4):641-8. Japanese.

13.

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.

Berwaerts J, Cleton A, Rossenu S, Talluri K, Remmerie B, Janssens L, Boom S, Kramer M, Eerdekens M.

J Psychopharmacol. 2010 Jul;24(7):1011-8. doi: 10.1177/0269881109106914. Epub 2009 Oct 13.

PMID:
19825908
14.

Applicability of (SBE)7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs).

Okimoto K, Tokunaga Y, Ibuki R, Irie T, Uekama K, Rajewski RA, Stella VJ.

Int J Pharm. 2004 Nov 22;286(1-2):81-8.

PMID:
15501004
15.

Abnormal dissolutions of chlorpromazine hydrochloride tablets in water by paddle method under a high agitation condition.

Aoyagi N, Rimando AP, Izutsu K, Katori N, Kojima S.

Chem Pharm Bull (Tokyo). 2003 Sep;51(9):1021-4.

16.
17.

In vivo/in vitro correlations for four differently dissolving ketorolac tablets.

Gordon MS, Chowhan Z.

Biopharm Drug Dispos. 1996 Aug;17(6):481-92.

PMID:
8866039
18.

Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.

Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M.

Am J Geriatr Psychiatry. 2008 Jan;16(1):31-43. doi: 10.1097/JGP.0b013e31815a3e7a.

PMID:
18165460
19.

Effect of hydrodynamic environment on tablets dissolution rate.

Wu Y, Kildsig DO, Ghaly ES.

Pharm Dev Technol. 2004;9(1):25-37.

PMID:
15000464
20.

A better dissolution method for ranitidine tablets USP.

Cappola ML.

Pharm Dev Technol. 2001;6(1):11-7.

PMID:
11247270

Supplemental Content

Support Center